AstraZeneca PLC's second-quarter performance is likely to be hit by ongoing drug pricing pressures, generic erosion and lower than expected externalization revenue. These factors will nevertheless be overshadowed by imminent data from the Phase III MYSTIC trial and ongoing speculation around CEO Pascal Soriot's recent visit to Israel.
AstraZeneca's 2Q earnings, to be reported on July 27, will highlight growing pressures on the company's more established drugs and...